Cargando…

Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

BACKGROUND AND OBJECTIVE: Gilteritinib is a novel, highly selective tyrosine kinase inhibitor approved in the USA, Canada, Europe, Brazil, Korea, and Japan for the treatment of FLT3 mutation-positive acute myeloid leukemia. This article describes the clinical pharmacokinetic profile of gilteritinib....

Descripción completa

Detalles Bibliográficos
Autores principales:	James, Angela Joubert, Smith, Catherine C., Litzow, Mark, Perl, Alexander E., Altman, Jessica K., Shepard, Dale, Kadokura, Takeshi, Souda, Kinya, Patton, Melanie, Lu, Zheng, Liu, Chaofeng, Moy, Selina, Levis, Mark J., Bahceci, Erkut
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550323/ https://www.ncbi.nlm.nih.gov/pubmed/32304015 http://dx.doi.org/10.1007/s40262-020-00888-w

Ejemplares similares

Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
por: James, Angela Joubert, et al.
Publicado: (2021)

The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia
por: Altman, Jessica K., et al.
Publicado: (2020)

Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib
por: Smith, Catherine C., et al.
Publicado: (2022)

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
por: Daver, Naval, et al.
Publicado: (2022)

Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study
por: Perl, Alexander E., et al.
Publicado: (2017)

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
por: Perl, Alexander E., et al.
Publicado: (2022)

Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
por: Perl, Alexander E., et al.
Publicado: (2022)

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells
por: Kawase, Tatsuya, et al.
Publicado: (2019)

Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy
por: Perl, Alexander E., et al.
Publicado: (2023)

Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
por: Chew, Serena, et al.
Publicado: (2020)

Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia
por: Marjoncu, Dennis, et al.
Publicado: (2020)

Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia
por: McCall, David, et al.
Publicado: (2021)

Cost-effectiveness of gilteritinib for relapsed/refractory FLT3(mut+) acute myeloid leukemia
por: Pandya, Bhavik J, et al.
Publicado: (2021)

Gilteritinib Affects the Selection of Dominant Clones in Clonal Hematopoiesis: Sequential Genetic Analysis of an FLT3-ITD Positive AML Patient with Long-Term Gilteritinib Therapy
por: Katagiri, Seiichiro, et al.
Publicado: (2023)

Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open‐label phase 1 study
por: Usuki, Kensuke, et al.
Publicado: (2018)

Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD(+) acute myeloid leukemia
por: Ueno, Yoko, et al.
Publicado: (2019)

BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors
por: Buelow, Daelynn R., et al.
Publicado: (2022)

Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML Patients
por: Molica, Matteo, et al.
Publicado: (2023)

Evaluation of hypereosinophilia in a case of FLT3-mutant acute myeloid leukemia treated with gilteritinib
por: Martinez-Gutierrez, Leslie N., et al.
Publicado: (2023)

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
por: Mori, Masamichi, et al.
Publicado: (2017)

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3(mut+) AML ineligible for intensive chemotherapy
por: Wang, Eunice S., et al.
Publicado: (2022)

Petromurin C Induces Protective Autophagy and Apoptosis in FLT3-ITD-Positive AML: Synergy with Gilteritinib
por: Ha, You Na, et al.
Publicado: (2020)

Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
por: Hosono, Naoko, et al.
Publicado: (2021)

Therapeutic Management of Patients with FLT3 + Acute Myeloid Leukemia: Case Reports and Focus on Gilteritinib Monotherapy
por: Bocchia, Monica, et al.
Publicado: (2022)

Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
por: Zhang, Yvyin, et al.
Publicado: (2023)

FLT3 dancing on the stem cell
por: Levis, Mark
Publicado: (2017)

Favorable pharmacokinetic and pharmacodynamic properties of gilteritinib in cerebrospinal fluid: a potential effective treatment in relapsing meningeal acute myeloid leukemia FLT3-ITD patients
por: Vignal, Nicolas, et al.
Publicado: (2023)

FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors
por: Nguyen, Bao, et al.
Publicado: (2017)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
por: Iannotta, R., et al.
Publicado: (2022)

Interim results from a postmarketing surveillance study of patients with FLT3-mutated relapsed/refractory AML treated with the FLT3 inhibitor gilteritinib in Japan
por: Sugamori, Haruko, et al.
Publicado: (2022)

FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation
por: Zhu, Ruiqi, et al.
Publicado: (2021)

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
por: Qiao, Xinan, et al.
Publicado: (2021)

P575: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR FLT3 MUTATED ACUTE MYELOID LEUKEMIA
por: Žučenka, Andrius, et al.
Publicado: (2023)

Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets
por: Kasi, Pashtoon M., et al.
Publicado: (2016)

Further Activation of FLT3 Mutants by FLT3 Ligand
por: Zheng, Rui, et al.
Publicado: (2011)

Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia
por: Kim, Lisa, et al.
Publicado: (2021)

Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3(mut) AML
por: Terao, Toshiki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1urjmb5kp3glpp0jk7927u47dj